News Buzz: Teva Pharmaceutical Industries (NYSE:TEVA), World Acceptance (NASDAQ:WRLD), AngioDynamics (NASDAQ:ANGO), The Boeing Company (NYSE:BA)

Pfizer and GlaxoSmithKline are among pharmaceutical companies whose shares advanced after announcing $115 billion of acquisition plans since the end of March. “It’s been like a game of Pac-Man,” said Timothy Chiang, an analyst at CRT Capital Group. Mylan has attempted to negotiate a takeover of Meda, while Chiang said Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has everyone wondering whether it’s going to seek a … Continue reading News Buzz: Teva Pharmaceutical Industries (NYSE:TEVA), World Acceptance (NASDAQ:WRLD), AngioDynamics (NASDAQ:ANGO), The Boeing Company (NYSE:BA)

Biotech Pre-Market Movers: Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA), Synergy Pharmaceuticals Inc(NASDAQ:SGYP), Pfizer Inc.(NYSE:PFE), AstraZeneca plc (ADR)(NYSE:AZN)

The American Despositary Receipts of Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA) edged up in recent pre-market trading on Monday after announcing over the weekend an agreement it has signed with Takeda Pharmaceutical for the marketing and sale of Rasagiline in Japan. Rasagiline is a treatment for Parkinson’s Disease developed by TEVA and has been approved in over 40 countries. TEVA closed at $48.69 on Friday in … Continue reading Biotech Pre-Market Movers: Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA), Synergy Pharmaceuticals Inc(NASDAQ:SGYP), Pfizer Inc.(NYSE:PFE), AstraZeneca plc (ADR)(NYSE:AZN)

Drug Stocks In News: Teva Pharmaceutical Industries (NYSE:TEVA), Allergan (NYSE:AGN), Dynavax Technologies Corporation (NASDAQ:DVAX), ISIS Pharmaceuticals (NASDAQ:ISIS)

Teva Pharmaceutical Industries Ltd. (ADR) (NYSE:TEVA) announces the launch of the generic equivalent to Lunesta(R) (Eszopiclone Tablets, CIV), 1, 2 and 3 mg, in the United States. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock performance was -0.68% in last session and finished the day at $49.61. Traded volume was 2,806.00million shares in the last session and the average volume of the stock remained 7.21million shares. … Continue reading Drug Stocks In News: Teva Pharmaceutical Industries (NYSE:TEVA), Allergan (NYSE:AGN), Dynavax Technologies Corporation (NASDAQ:DVAX), ISIS Pharmaceuticals (NASDAQ:ISIS)

Healthcare Most Active Stocks: Teva Pharmaceutical Industries (NYSE:TEVA), Johnson & Johnson (NYSE:JNJ), MannKind Corporation (NASDAQ:MNKD), Abbott Laboratories (NYSE:ABT)

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is one of half a dozen drugmakers that have been rolling out generics of Eli Lilly’s ($LLY) top-selling blockbuster Cymbalta. The others are going to roll past the Israeli drugmaker after it recalled more than 1 million bottles of the antidepressant. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock performance was -0.76% in last session and finished the day at … Continue reading Healthcare Most Active Stocks: Teva Pharmaceutical Industries (NYSE:TEVA), Johnson & Johnson (NYSE:JNJ), MannKind Corporation (NASDAQ:MNKD), Abbott Laboratories (NYSE:ABT)

FB Nasdaq FB Facebook

Drug Manufacturer Stocks: Teva Pharmaceutical Industries (NYSE:TEVA), Prana Biotechnology (NASDAQ:PRAN), Amarin Corporation (NASDAQ:AMRN), Depomed Inc (NASDAQ:DEPO)

National Alliance Securities assumed coverage on shares of Teva Pharmaceutical Industries Ltd (ADR) (NASDAQ:TEVA) in a research note issued to investors on Monday, Analyst Ratings Netreports. The firm issued a buy rating and a $64.22 price target on the stock. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock performance was -1.18% in last session and finished the day at $50.90. Traded volume was 500.00million shares in … Continue reading Drug Manufacturer Stocks: Teva Pharmaceutical Industries (NYSE:TEVA), Prana Biotechnology (NASDAQ:PRAN), Amarin Corporation (NASDAQ:AMRN), Depomed Inc (NASDAQ:DEPO)

Healthcare Most Active Stocks: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Teva Pharmaceutical Industries (NYSE:TEVA), Bristol-Myers Squibb (NYSE:BMY)

During the trial, palbociclib — a pill — was combined with the standard anti-estrogen treatment Letrozole. The combined treatment resulted in a 26.1 month progression-free survival rate compared with only 7.5 months for Letrozole alone. Under development by Pfizer Inc. (NYSE:PFE), the medication used in the study is a selective inhibitor of cyclin-dependent kinases (CDK) 4 and 6. Pfizer Inc. (NYSE:PFE) stock performance was -1.06% … Continue reading Healthcare Most Active Stocks: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Teva Pharmaceutical Industries (NYSE:TEVA), Bristol-Myers Squibb (NYSE:BMY)